HCPCS code J0153: Adenosine injection 1 mg billing guide

Key takeaways

HCPCS code J0153 covers injection, adenosine, 1 mg. It is billed per 1 mg unit, most often for pharmacological cardiac stress testing.

J0153 took effect on January 1, 2015. It absorbed two codes deleted that day, J0150 (therapeutic use, 6 mg) and J0151 (diagnostic use, 1 mg).

J0153 must not be used for adenosine phosphate compounds. The exclusion sits inside the official descriptor, so misuse is a compliance violation.

Both branded adenosine products, Adenocard and Adenoscan, are discontinued. Almost every J0153 claim today carries a generic NDC.

NDC reporting is required on every Medicare Part B claim for J0153. Omitting the NDC is a top denial trigger.

Practice management software like Pabau attaches the NDC and applies the right fee schedule before a J0153 claim leaves the building.

HCPCS code J0153 is the current active code for adenosine injection, billed per 1 mg. The Centers for Medicare and Medicaid Services (CMS) maintains the official descriptor. It reads «Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds).» That parenthetical exclusion carries the same weight as the rest of the descriptor. Billing J0153 for an adenosine phosphate product is a compliance violation.

J0153 took effect on January 1, 2015. It replaced two codes deleted the same day. J0150 covered adenosine for therapeutic use in 6 mg increments, and J0151 covered adenosine for diagnostic use in 1 mg increments. HCPCS 2015 folded both into one per-milligram code that applies whether the drug is given to diagnose or to treat.

J0153 covers every adenosine injection product, branded or generic. The two branded versions, Adenocard and Adenoscan, both came from Astellas Pharma US and were manufactured by Hospira. FDA lists both as discontinued, so the supply reaching US practices today is generic.

The coder’s job is to confirm the administered drug is adenosine, not an adenosine phosphate compound. Units are then calculated from the dose given.

Clinical use: When is adenosine injection indicated?

Adenosine’s primary clinical application is pharmacological cardiac stress testing. When a patient cannot exercise adequately, physicians give adenosine as a vasodilator to mimic the effects of exertion. The drug dilates coronary arteries, revealing perfusion deficits that myocardial perfusion imaging (MPI) can capture. A thallium stress test is one common form of that imaging.

Adenosine also treats supraventricular tachycardia (SVT). That is a distinct clinical context with different billing considerations, so confirm the documented indication before selecting J0153. Outpatient infusion settings running IV therapy EMR software see both scenarios, and the drug record is what separates them.

• Myocardial perfusion imaging (MPI): The most common billing context for J0153. Adenosine is infused continuously during nuclear stress testing.
• Coronary flow reserve testing: Used alongside invasive coronary procedures in catheterization labs, where measures such as Fick cardiac output are recorded too.
• SVT treatment: Rapid IV bolus in emergency or outpatient settings. Confirm the product is adenosine, not an adenosine phosphate compound, before coding J0153.
• Pharmacological stress echocardiography: Less common. Verify payer policy first, since some MAC LCDs restrict coverage to specific imaging modalities.

J0153 billing guidelines and coding rules

Three rules govern every J0153 claim: correct unit count, NDC attachment, and proper place of service. Missing any one of them is the fastest route to a denial. Drug lines behave differently from procedure lines in medical billing, because the product itself has to be identified on the claim.

Units of service

J0153 is billed per 1 mg. If a patient receives 24 mg of adenosine during a stress test infusion, the claim should reflect 24 units. Coders must confirm the administered dose in the clinical note or infusion record, not default to a standard dose. Dose varies by patient weight and protocol.

Discarded drug and the JW and JZ modifiers

CMS requires a discarded-drug modifier on separately payable Part B drugs supplied in single-dose containers. Use JW on a separate line to report the amount discarded, and JZ on the J0153 line to attest that nothing was discarded. Check the packaging of the adenosine product you stock first, because multi-dose vials fall outside the requirement.

The modifier has to agree with the dose in the record. Say the note documents 24 mg drawn from a vial holding more. The discarded remainder belongs on a JW line, not folded into the billed units.

The adenosine phosphate compound exclusion

The exclusion in the J0153 descriptor is one of the most-cited compliance traps in J-code billing. Adenosine phosphate compounds are chemically distinct from adenosine and carry their own HCPCS codes. They are sometimes marketed for circulatory conditions or sold as nutritional supplements. Billing J0153 for one of them is incorrect regardless of payer.

Document the exact drug name and NDC from the administered vial before coding. The FDA NDC directory will confirm what the product actually contains.

Place of service

J0153 is billed in hospital outpatient departments, physician offices, ambulatory surgical centers (ASCs), and independent diagnostic testing facilities (IDTFs). The reimbursement rate differs by setting under the Medicare Outpatient Prospective Payment System (OPPS) versus the Physician Fee Schedule. Confirm the place of service code before release, since the same dose pays differently in an office and in a hospital.

J0153 fee schedule and Medicare reimbursement rates

Medicare pays for J0153 under the Average Sales Price (ASP) + 6% methodology. ASP-based rates are updated by CMS every quarter, so any specific dollar figure in a reference article is likely outdated within 90 days. Always pull the current rate before submitting a claim or verifying reimbursement. The CMS Physician Fee Schedule lookup and the quarterly ASP files are the two sources to use.

Reimbursement also differs by setting. The same J0153 claim submitted under the Physician Fee Schedule pays differently from a claim processed under OPPS at a hospital outpatient department. Practices should use practice management software that applies the correct fee schedule by place of service automatically. Manual rate lookups go stale within a quarter.

J0153 NDC crosswalk: Linking the drug to the claim

CMS requires that Medicare Part B claims for separately payable drugs include the National Drug Code (NDC) of the product administered. For J0153, the NDC reported must correspond to an adenosine injection product, not an adenosine phosphate formulation. That rule covers every separately payable Part B drug, including infusion products such as J2323.

The NDC-to-HCPCS crosswalk file published quarterly by CMS maps approved NDCs to J0153. Coders working from a stale crosswalk submit mismatched NDCs, which triggers automated denials. EHR integration that pulls the NDC at the point of dispensing removes most of that manual lookup.

The table below reflects representative manufacturers and product types. Verify against the current CMS crosswalk before submission, since generic manufacturers and NDC assignments change often. Practices that log every vial into inventory management keep the lot and expiration alongside the NDC, which is what an auditor asks for.

On a CMS-1500 or electronic claim, report the NDC in the shaded area of box 24A. On the 837P it belongs in loop 2410. Add the matching unit qualifier, which is UN for units, GR for grams, or F2 for international units. For adenosine, UN is the standard qualifier.

Related adenosine HCPCS codes: J0150, J0151, and J0152

Coders researching adenosine billing still run into J0150, J0151, and J0152. All three are deleted, and none of them can be submitted today. The table below shows what each one covered and when it was retired. That distinction matters, because only two of them are genuine predecessors of J0153.

J0150 and J0151 are the codes J0153 actually absorbed. Both were deleted on January 1, 2015, the day J0153 took effect. J0152 is the one that trips people up. It was deleted on January 1, 2014, a full year before J0153 existed, so treating it as a J0153 predecessor misreads the record.

The 2015 consolidation is what still catches older systems out. Charge masters built before that date often carry two adenosine lines, one for diagnostic use and one for therapeutic use. That is how the code set was structured at the time. That split is gone. One code now carries every adenosine injection claim, and the unit count does all the work.

CPT codes commonly billed alongside J0153 for stress testing

J0153 is almost never submitted in isolation. The drug is the billable component, but the imaging or monitoring procedure carries its own CPT code. Payers link the drug’s coverage to the procedure’s indication, so a supervision or component error on 93015 can take the drug line down with it.

Outside stress testing, the administration code changes. When adenosine is pushed to convert SVT, the service is reported with 96374 rather than a stress test CPT.

ICD-10 diagnosis codes that support medical necessity

Payers tie adenosine coverage to the reason the stress test was ordered. The diagnosis on the claim has to explain why the patient needed pharmacological stress instead of exercise. Arrhythmia diagnoses such as I49.9 show up instead when adenosine is given to treat rather than to test.

The codes below appear most often on J0153 claims. Every MAC publishes its own covered list, so check the LCD for your jurisdiction before relying on any of them.

The diagnosis alone rarely carries a claim through a prepayment review. Pair it with a note explaining why exercise stress was ruled out. Beta blocker therapy, orthopedic limitation, deconditioning, and left bundle branch block are the reasons MACs see most often on adenosine claims.

Diabetes and obesity sit behind many of those referrals, so practices running a metabolic health EMR handle these claims regularly. A medication review before the appointment matters too, since caffeine and methylxanthines blunt adenosine’s effect.

Payer coverage and prior authorization for HCPCS code J0153

Medicare Part B covers adenosine injection (J0153) for pharmacological cardiac stress testing when the clinical documentation supports medical necessity. CMS Local Coverage Determinations (LCDs) issued by Medicare Administrative Contractors (MACs) govern the specific covered indications. Coverage for other uses, such as SVT treatment in outpatient settings, varies by MAC jurisdiction.

Payer policy review belongs in the practice’s revenue cycle management routine rather than in a scramble after the first denial. LCDs change between the annual code updates, and nobody sends a reminder.

• Medicare Part B: Covers adenosine for pharmacological stress testing. The record must document why exercise stress was inadequate and show a clinically appropriate imaging protocol.
• Commercial payers: Coverage criteria vary significantly by plan. Some require preauthorization for nuclear stress tests and others do not, so verify benefits before scheduling.
• Prior authorization: Not universally required by Medicare for J0153 itself. The accompanying imaging CPT may still trigger a review under commercial plans.
• MAC LCD review: Pull the relevant LCD from your MAC’s website before billing adenosine for any indication outside standard stress testing protocols.

Documentation requirements for J0153 claims

Every J0153 claim rests on three documented facts. The record has to show which drug was given, how much of it, and why the patient needed pharmacological stress. Auditors read the clinical note, not the claim form, so anything missing from the chart is effectively missing from the claim.

• Drug name as printed on the vial: The generic or branded product name, with the manufacturer noted.
• NDC and lot number: The 11-digit NDC from the administered vial or the pharmacy dispensing record, plus lot and expiration date.
• Total dose in milligrams: Recorded as a number rather than a protocol name, since the unit count is derived from it.
• Route and timing: Infusion route with start and stop times, which support both the drug line and the stress test CPT.
• Any discarded amount: Documented in the record whenever a JW modifier is reported on the claim.
• Clinical indication: The ordering physician’s stated reason, including why exercise stress testing was inadequate or contraindicated.
• Supervision: Evidence that the required level of physician supervision was in place during the infusion.
• Adverse reactions: Any reaction to the infusion and the treatment given in response.

Clean medical forms that capture these fields at the point of care cut the risk of medical necessity denials sharply. A structured medication log template gives the infusion nurse one place to record drug, dose, lot, and time.

Rebuilding a record months later, from a partial infusion log and a nurse’s memory, rarely satisfies an auditor. Storage and retrieval matter as much as capture, which is where HIPAA compliance for medical offices sets the bar.

How to bill J0153: Step-by-step claim submission

Code lookup is only the first step. The workflow below runs from clinical confirmation through to claim submission.

1. Confirm the drug administered: Verify the administered drug is adenosine and not an adenosine phosphate compound. Pull the drug name and NDC straight from the vial or the pharmacy dispensing record.
2. Calculate units: Divide the total administered dose in mg by 1. If the patient received 18 mg, report 18 units of J0153.
3. Identify the NDC: Read the NDC off the vial label. Labels often print 10 digits, so pad the short segment with a leading zero to reach the 5-4-2 format payers expect. Mylan’s adenosine 3 mg/mL vial is labeled 67457-856-20, which becomes 67457-0856-20 on the claim. Confirm the NDC still maps to J0153 in the current CMS crosswalk, published with the quarterly ASP pricing files.
4. Select the place of service: Confirm whether the service was delivered in a physician office (POS 11), outpatient hospital (POS 22), or ASC (POS 24). The reimbursement rate differs by setting.
5. Pair with the correct CPT: Attach the applicable imaging or monitoring CPT from the pairing table above. Check that the ICD-10 diagnosis supports medical necessity for both the drug and the procedure.
6. Submit the claim: Report J0153 on its own line with units, NDC, the UN qualifier, and the NDC dose quantity. Submit it alongside the CPT codes for the stress test and imaging.

Common billing errors and compliance risks with HCPCS code J0153

Adenosine claims have a predictable set of failure patterns. Practices that track their denial reasons find the same errors arriving in batches. Fixing the root cause on one claim reduces exposure across an entire service line.

How practice management software keeps J0153 claims clean

Most adenosine denials start well upstream of the biller. The dose sits in a nursing note. The NDC was on a vial that has already been discarded, and the charge master still carries a code CMS retired in 2015. By the time anyone builds the claim, the evidence has scattered across three systems.

Pabau keeps those pieces in one patient record. The drug, dose, NDC, and administration times are captured at the point of care. The biller then works from the same chart the clinician wrote in. Nothing has to be rekeyed between systems, which is where most unit-count errors are born.

Pabau’s claims management tools carry those fields onto the claim itself. They apply the fee schedule that matches the place of service. A J0153 line with no NDC attached is flagged before it goes out. Every subscription includes them, so none of this sits behind a higher plan.

The outcome is fewer returned claims and far less time spent rebuilding documentation for an audit. Your coders stop chasing the infusion room for a number that belongs in the chart. Adenosine claims go out right the first time.

Automate drug billing workflows in your practice

Pabau’s claims management software helps cardiology and multi-specialty practices track drug administration, attach NDCs automatically, and submit clean J-code claims the first time.

Book a demo

Conclusion

J0153 is a straightforward per-unit drug code with a compliance trap built into its descriptor. Document the dose precisely, verify the NDC at dispensing, and pair the drug with the right imaging CPT. Practices that do those three things see far fewer denials on adenosine claims.

Two housekeeping jobs are worth an afternoon. Clear J0150, J0151, and J0152 out of the charge master, since all three are long gone. Then swap any legacy Adenocard or Adenoscan NDC for the generic product on your shelf, because the branded versions are discontinued.

Pabau’s claims management software builds these checks into the billing workflow, so coders spend less time verifying by hand. Book a demo to see how drug claim submission, NDC tracking, and payer-specific rules run in one system.

Continue your research

Billing the stress test itself, not just the drug? CPT code 93015 breaks down supervision, components, and the split-billing rules that decide whether the J0153 line survives.

Need the administration code for a rapid IV push? CPT code 96374 covers push billing, the modifiers involved, and the documentation payers ask for.

Comparing tools that scrub claims before they go out? Pabau vs. Waystar compares how each one handles claim edits, submission, and denial follow-up.

Billing an infusion catheter alongside the drug? HCPCS code C1751 explains device coding and the packaging rules that apply in outpatient settings.

Coding anesthesia for a cardiac catheterization? CPT code 01920 sets out base units, time reporting, and the modifiers that go with cath lab cases.

Frequently asked questions